<DOC>
	<DOCNO>NCT01208792</DOCNO>
	<brief_summary>The investigator recently evidence presence antibody endothelial cell fibroblasts patient idiopathic SSc-associated PAH . The investigator also identify several target antigen anti-fibroblasts antibody . The objective study investigate presence antibody endothelial cell fibroblasts patient characterize antigen specificity autoantibody patient different type non idiopathic non SSc-associated PAH , PAH associate HIV infection , porto-pulmonary hypertension , congenital heart disease , systemic lupus erythematosus , mixed connective tissue disease Sjögren 's syndrome</brief_summary>
	<brief_title>Auto-immunity Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Two hundred fifty patient PAH include : 65 patient idiopathic PAH ( iPAH ) , 20 PAH associate HIV infection , 20 porto-pulmonary hypertension , 20 PAH secondary congenital heart disorder , 40 SSc , 20 SLE , 20 MCTD 10 PAH associate Sjögren 's syndrome . Two hundred patient without PAH also include : 80 patient SSc 20 follow group : HIV infection , porto-pulmonary hypertension , SLE , congenital heart disorder , MCTD Sjögren 's syndrome . Twenty patient proximal chronic thromboembolic pulmonary hypertension ( CTPH ) also include control arm study . Two hundred fifty healthy blood donor age sex-matched patient PAH , include control . By use 2D-immunoblotting technique , evidence IgG antibody fibroblast , EC , vascular smooth muscle cell ( SMC ) multiple group patient characterize target antigens autoantibody . We also assess production ROS : nitric oxide ( NO ) , hydrogen peroxide ( H2O2 ) effect whole serum ( IgG particularly ) VITRO proliferation EC , fibroblasts vascular SMC . For serum induce production ROS , study effect different vasodilatator ( prostacycline , endothelin receptor antagonist , type 5 phosphodiesterase inhibitor ) anti-oxidant therapy . Expected result We characterize target antigens autoantibody patient non-idiopathic non SSc-associated PAH . We compare target previously identify idiopathic SSc-associated PAH . We , distinguish subpopulation PAH patient whose serum purify IgG ( possibly specific give antigen ) able induce ROS production cell proliferation . For population ROS-producer patient , correlate clinical response vasodilatator therapy result VITRO inhibition experiment vasodilatators anti-oxidant molecule . Perspectives The characterization target antigen EC , fibroblasts vascular SMC specifically</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>age 18 PAH patient : precapillary PAH evidence rightheart catheterization associate systemic disease idiopathic PAH patient HIV patient , HIV1 infection confirm ELISA western blot patient porto pulmonary hypertension : evidence endoscopy esophageal varix , confirmation hepatic venous pressure gradient 5 mmHg catheterization hepatic vein patient congenital heart defect : evidence image atrial ventricular septal defect , patent ductus arterious confirm heart catheterization patient SSc fulfill American College Rheumatology ( ACR ) LEROY MEDSGER criterion patient MCTD fulfill criterion MCTD patient SLE fulfill update revise ACR criterion patient Sjögren 's syndrome fulfill AmericanEuropean consensus group criteria patient chronic thromboembolic pulmonary hypertension : Lung scintiscan showing segmental mismatch perfusion defect confirmation angiography occlusion chance success endarterectomy accord location disease Signed write informed consent Patients health insurance age 18 pregnant woman absence write informed consent associate malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Auto antibody</keyword>
	<keyword>Target antigen</keyword>
	<keyword>2D-immunoblot</keyword>
	<keyword>Reactive oxygen specie</keyword>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Human immunodeficiency virus infection</keyword>
	<keyword>Porto pulmonary hypertension</keyword>
	<keyword>Congenital heart defect</keyword>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>Mixed connective tissue disease</keyword>
	<keyword>Sjögren 's syndrome</keyword>
</DOC>